Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/JCP.0000000000001908 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tapentadol Withdrawal Dystonia in a Young Adult Male Patient With Opioid Use Disorder.
J Clin Psychopharmacol
January 2024
Department of Psychiatry, All India Institute of Medical Sciences (AIIMS), Bathinda, India
Tapentadol: navigating the complexities of abuse, patient safety & regulatory measures.
Curr Med Res Opin
December 2024
Public Health, Indian Pharmacopoeia Commission, Ministry of Health & Family Welfare, Ghaziabad, India.
Aim: To evaluate tapentadol abuse cases by analyzing real-world data and identifying under-reporting countries from Southeast Asian Region (SEAR) to enhance vigilance.
Method: A retrospective, observational study from 2013 to March 2024 using VigiBase was conducted.
Result: Tapentadol-related abuse falls within the System Organ Class (SOC) categories of psychiatric disorder, nervous system disorder and injury, poisoning, and procedural complications.
Considerations for perioperative opioid analgesic stewardship in Australia: a focus on tapentadol.
Pain Manag
May 2023
CSL-Seqirus Medical Affairs 655 Elizabeth Street Melbourne Victoria, Australia.
Opioid-related harm remains a serious public health issue in Australia, where there is a strong focus on judicious use of opioids to optimize postoperative patient outcomes. The risks associated with preoperative opioid use (worsened postoperative pain, surgical outcomes, increased length of stay and financial costs) must be balanced with the risks of sub-optimal post-surgical pain management (development of chronic pain, persistent postsurgical opioid use and opioid dependence). In addition to significantly lower rates of gastrointestinal adverse effects (nausea, vomiting, constipation), tapendatol (vs oxycodone) is less likely to cause excessive sedation and opioid-induced ventilatory impairment, may be associated with less withdrawal symptoms of mild to moderate intensity and significantly lower odds of 3-month persistent postoperative opioid use in certain patient populations.
View Article and Find Full Text PDFReducing Opioid Use for Chronic Pain With a Group-Based Intervention: A Randomized Clinical Trial.
JAMA
May 2023
Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, United Kingdom.
Importance: Opioid use for chronic nonmalignant pain can be harmful.
Objective: To test whether a multicomponent, group-based, self-management intervention reduced opioid use and improved pain-related disability compared with usual care.
Design, Setting, And Participants: Multicentered, randomized clinical trial of 608 adults taking strong opioids (buprenorphine, dipipanone, morphine, diamorphine, fentanyl, hydromorphone, methadone, oxycodone, papaveretum, pentazocine, pethidine, tapentadol, and tramadol) to treat chronic nonmalignant pain.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!